The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug’s significant clinical and statistical benefits over a placebo in treating depression.

CEO Steve Gourlay emphasised its potential as a safer and more effective alternative to current antidepressants, particularly for patients with milder forms of depression.

The trial results showed early and lasting improvements in depressive symptoms, and it’s unique mechanism of reducing chronic stress by lowering cortisol levels which sets it apart from other treatments.

Actinogen Medical is now completing the trial analysis, engaging with potential strategic partners, and continuing their Alzheimer’s research in a phase two B trial, aiming to show that Xanamem can also slow the progression of Alzheimer’s disease.

Disclaimer: The Market Online has a commercial relationship with Actinogen.

ACW by the numbers
More From The Market Online
A Black Cat Syndicate truck drives into the Paulsens gold mine opening.

‘Immensely proud’: Golden day for Black Cat Syndicate after first Paulsens pour

Black Cat Syndicate (ASX:BC8) has scored a golden victory right before Christmas, with the Western Australian explorer recording its
Mining work at CZR Resources' for-sale Robe Mesa iron ore project.

Still no approval 12 months on: FIRB wait forces CZR Resources to kick $102M Robe Mesa sale down road again

CZR Resources (ASX:CZR) has been forced to
The words "Market Open" appear stacked atop one another next to ASX company iconography.

ASX Market Open: Operator beats weekend’s tech outage to get Aussie bourse open for green Monday | Dec 23, 2024

First thing first, yes the ASX will be open today – the Aussie bourse was in serious danger of being closed through December